The present invention discloses the protease hepsin is specifically over-expressed in ovarian and other malignancies. A number of hepsin peptides can induce immune responses to hepsin, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies. There is also provided a hepsin protein variant that is useful as a marker for ovarian cancer cells, prostate cancer cells or kidney cancer cells.

Board of Trustees of the University of Arkansas

Methods for the early diagnosis of ovarian cancer

Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumor cells that also express the putative tumor stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumor cells and also as a therapeutic agent for treating cancers, tumors and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumor, renal tumor, prostate cancer, sarcoma and/or melanoma.

MONASH UNIVERSITY

MEMORIAL SLOAN-KETTERING CANCER CENTRE

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

Lackmann; Beate

Monash University

Memorial Sloan-Kettering Cancer Centre

Ludwig Institute for Cancer Research Ltd.

Anti-metalloprotease antibody for diagnosis and treatment of cancers

kidney neoplasms

protease

kidney neoplasms/protease

Methods for the early diagnosis of ovarian cancer

Anti-metalloprotease antibody for diagnosis and treatment of cancers

La base de données d'herbes médicinales la plus complète soutenue par la science